Towards the introduction of the 'Immunoscore'in the classification of malignant tumours

J Galon, B Mlecnik, G Bindea, HK Angell… - The Journal of …, 2014 - Wiley Online Library
Abstract The American Joint Committee on Cancer/Union Internationale Contre le Cancer
(AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine …

[HTML][HTML] Cancer classification using the Immunoscore: a worldwide task force

J Galon, F Pagès, FM Marincola, HK Angell… - Journal of translational …, 2012 - Springer
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation
of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor …

[HTML][HTML] Validation of biomarkers to predict response to immunotherapy in cancer: volume I—pre-analytical and analytical validation

GV Masucci, A Cesano, R Hawtin, S Janetzki… - … for immunotherapy of …, 2016 - Springer
Immunotherapies have emerged as one of the most promising approaches to treat patients
with cancer. Recently, there have been many clinical successes using checkpoint receptor …

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

F Pagès, B Mlecnik, F Marliot, G Bindea, FS Ou… - The Lancet, 2018 - thelancet.com
Background The estimation of risk of recurrence for patients with colon carcinoma must be
improved. A robust immune score quantification is needed to introduce immune parameters …

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

I Poschke, D Mougiakakos, J Hansson, GV Masucci… - Cancer research, 2010 - AACR
Myeloid-derived suppressor cells (MDSC) have emerged as key immune modulators in
various tumor models and human malignancies, but their characteristics in humans remain …

[HTML][HTML] Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to …

B Mlecnik, C Bifulco, G Bindea, F Marliot… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The purpose of this study was to evaluate the prognostic value of Immunoscore
in patients with stage III colon cancer (CC) and to analyze its association with the effect of …

Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection?

L Festino, G Botti, P Lorigan, GV Masucci, JD Hipp… - Drugs, 2016 - Springer
Strategies to help improve the efficacy of the immune system against cancer represent an
important innovation, with recent attention having focused on anti-programmed death (PD) …

[HTML][HTML] Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma

YP de Coana, M Wolodarski, I Poschke, Y Yoshimoto… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Ipilimumab has revolutionized malignant melanoma therapy, but a better understanding of
the mechanisms behind treatment response and adverse effects is needed. In this work, the …

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production

YP de Coaña, I Poschke, G Gentilcore, Y Mao… - Cancer immunology …, 2013 - AACR
Blocking the immune checkpoint molecule CTL antigen-4 (CTLA-4) with ipilimumab has
proven to induce long-lasting clinical responses in patients with metastatic melanoma. To …

[HTML][HTML] Validation of biomarkers to predict response to immunotherapy in cancer: volume II—clinical validation and regulatory considerations

KK Dobbin, A Cesano, J Alvarez, R Hawtin… - … for immunotherapy of …, 2016 - Springer
There is growing recognition that immunotherapy is likely to significantly improve health
outcomes for cancer patients in the coming years. Currently, while a subset of patients …